SUMM Summit Therapeutics Plc

 
TIDMSUMM 
 
   Summit Therapeutics plc 
 
   ('Summit' or the 'Company') 
 
   Director Change 
 
   Oxford, UK, and Cambridge, MA, US, 11 October 2019 -- Summit 
Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) a leader in new mechanism 
antibiotic innovation, announces that Valerie Andrews, a Non-Executive 
Director, is stepping down from the board of the Company with effect 
from today. The Board will continue to assess its composition to ensure 
it is supporting the future development of the business. 
 
   Dr Frank Armstrong, Chairman of Summit Therapeutics, commented: "I would 
like to recognise Val's considerable contribution to Summit and thank 
her for her commitment to the Company over the last five years.  Val has 
provided valuable insight and expertise in her roles across the Board 
and committees. We all wish her every success for the future." 
 
   Ms. Valerie Andrews added: "It has been a privilege to play a role in 
supporting the growth and development of Summit. With the Company's 
dedication to developing new class, targeted antibiotics that focus on 
better outcomes for patients, I believe that the Company is well 
positioned to fulfil its undoubted promise in this important field of 
medical research." 
 
   This announcement contains inside information for the purposes of 
Article 7 of EU Regulation 596/2014 (MAR). 
 
   About Summit Therapeutics 
 
   Summit Therapeutics is a leader in antibiotic innovation. Our new 
mechanism antibiotics are designed to become the new standards of care 
for the benefit of patients and create value for payors and healthcare 
providers. We are currently developing new mechanism antibiotics for 
infections caused by C. difficile, N. gonorrhoeae and Enterobacteriaceae 
and are using our proprietary Discuva Platform to expand our pipeline. 
For more information, visit www.summitplc.com and follow us on Twitter 
@summitplc. 
 
   Contacts 
 
 
 
 
Summit                                               Tel: +44 (0)1235 443 951 
 Glyn Edwards / Richard Pye (UK office)               +1 617 225 4455 
 Michelle Avery (US office) 
 
Cairn Financial Advisers LLP (Nominated Adviser)     Tel: +44 (0)20 7213 0880 
 Liam Murray / Tony Rawlinson / Ludovico Lazzaretti 
 
N+1 Singer (Joint Broker)                            Tel: +44 (0)20 7496 3000 
 Aubrey Powell / Jen Boorer, Corporate Finance 
 Tom Salvesen, Corporate Broking 
 
Bryan Garnier & Co Limited (Joint Broker)            Tel: +44 (0)20 7332 2500 
 Phil Walker / Dominic Wilson 
 
MSL Group (US)                                       Tel: +1 781 684 6652 
 Erin Anthoine                                        summit@mslgroup.com 
                                                     --------------------------- 
 
Consilium Strategic Communications (UK)              Tel: +44 (0)20 3709 5700 
 Mary-Jane Elliott / Sue Stuart /                     summit@consilium-comms.com 
 Sukaina Virji / Lindsey Neville 
                                                     --------------------------- 
 
 
   -END- 
 
 
 
 

(END) Dow Jones Newswires

October 11, 2019 07:01 ET (11:01 GMT)

Grafico Azioni Summit Therapeutics (LSE:SUMM)
Storico
Da Mar 2024 a Apr 2024

Grafico Azioni Summit Therapeutics (LSE:SUMM)
Storico
Da Apr 2023 a Apr 2024